RxDoctor Payments Data

Stephanie Georgaklis, PA

Physician Assistant · Nashua, NHNPI 1780988477

Payments from drug & device makers

$1,446in general payments, 2019–2025

Across 38 payments — averaging $38.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$501
  • AstraZeneca$350
  • Abbott$149
  • Medtronic$126
  • Johnson & Johnson$119
  • Pfizer$70
  • plus $130 from 4 others

What the payments were for

  • Food & beverage$1,33392%
  • Education$1138%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,446 in reported general payments places this provider in the 90th percentile of 782 physician assistant providers in New Hampshire.

See all physician assistant providers in New Hampshire

Medicare billing

Part B allowed, 2024
$52,014
Medicare patients
448
Services billed
1,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban266$316,183
XareltoRivaroxaban95$123,953
Repatha SureclickEvolocumab84$68,361
EntrestoSacubitril/Valsartan60$62,984
FarxigaDapagliflozin Propanediol41$38,491
JardianceEmpagliflozin28$32,963
Praluent PenAlirocumab22$19,359
Metoprolol Succinate366$4,888
PradaxaDabigatran Etexilate Mesylate15$3,702
Rosuvastatin Calcium240$3,592
Atorvastatin Calcium283$3,284
Flecainide Acetate58$2,655
Ezetimibe85$2,042
Valsartan64$1,796
Diltiazem 24hr ErDiltiazem Hcl20$1,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$316,183266 claims
Johnson & JohnsonXarelto$119$123,95395 claims
NovartisEntresto$57$62,98460 claims
AstraZenecaFarxiga$350$38,49141 claims
Boehringer IngelheimJardiance, Pradaxa$23$36,66543 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 782 physician assistant providers in New Hampshire.

Other physician assistant in Nashua

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →